Cotargeting of CYP-19 (aromatase) and emerging, pivotal signalling pathways in metastatic breast cancer

Aromatase inhibition is one of the cornerstones of modern endocrine therapy of oestrogen receptor-positive (ER+) metastatic breast cancer (MBC). The nonsteroidal aromatase inhibitors anastrozole and letrozole, as well as the steroidal aromatase inactivator exemestane, are the preferred drugs and est...

Descripción completa

Detalles Bibliográficos
Autores principales: Daldorff, Stine, Mathiesen, Randi Margit Ruud, Yri, Olav Erich, Ødegård, Hilde Presterud, Geisler, Jürgen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5220158/
https://www.ncbi.nlm.nih.gov/pubmed/27923036
http://dx.doi.org/10.1038/bjc.2016.405

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5220158/
https://www.ncbi.nlm.nih.gov/pubmed/27923036
http://dx.doi.org/10.1038/bjc.2016.405

Ejemplares similares